261 related articles for article (PubMed ID: 24820309)
1. Loss of Stat1 decreases megakaryopoiesis and favors erythropoiesis in a JAK2-V617F-driven mouse model of MPNs.
Duek A; Lundberg P; Shimizu T; Grisouard J; Karow A; Kubovcakova L; Hao-Shen H; Dirnhofer S; Skoda RC
Blood; 2014 Jun; 123(25):3943-50. PubMed ID: 24820309
[TBL] [Abstract][Full Text] [Related]
2. The role of JAK2 V617F mutation, spontaneous erythropoiesis and megakaryocytopoiesis, hypersensitive platelets, activated leukocytes, and endothelial cells in the etiology of thrombotic manifestations in polycythemia vera and essential thrombocythemia.
Bellucci S; Michiels JJ
Semin Thromb Hemost; 2006 Jun; 32(4 Pt 2):381-98. PubMed ID: 16810614
[TBL] [Abstract][Full Text] [Related]
3. Molecular pathogenesis and therapy of polycythemia induced in mice by JAK2 V617F.
Zaleskas VM; Krause DS; Lazarides K; Patel N; Hu Y; Li S; Van Etten RA
PLoS One; 2006 Dec; 1(1):e18. PubMed ID: 17183644
[TBL] [Abstract][Full Text] [Related]
4. Deletion of Stat3 in hematopoietic cells enhances thrombocytosis and shortens survival in a JAK2-V617F mouse model of MPN.
Grisouard J; Shimizu T; Duek A; Kubovcakova L; Hao-Shen H; Dirnhofer S; Skoda RC
Blood; 2015 Mar; 125(13):2131-40. PubMed ID: 25595737
[TBL] [Abstract][Full Text] [Related]
5. Distinct effects of V617F and exon12-mutated JAK2 expressions on erythropoiesis in a human induced pluripotent stem cell (iPSC)-based model.
Nilsri N; Jangprasert P; Pawinwongchai J; Israsena N; Rojnuckarin P
Sci Rep; 2021 Mar; 11(1):5255. PubMed ID: 33664283
[TBL] [Abstract][Full Text] [Related]
6. Megakaryopoiesis and platelet function in polycythemia vera and essential thrombocythemia patients with JAK2 V617F mutation.
Hattori N; Fukuchi K; Nakashima H; Maeda T; Adachi D; Saito B; Yanagisawa K; Matsuda I; Nakamaki T; Gomi K; Tomoyasu S
Int J Hematol; 2008 Sep; 88(2):181-188. PubMed ID: 18612778
[TBL] [Abstract][Full Text] [Related]
7. JAK2 V617F stimulates proliferation of erythropoietin-dependent erythroid progenitors and delays their differentiation by activating Stat1 and other nonerythroid signaling pathways.
Shi J; Yuan B; Hu W; Lodish H
Exp Hematol; 2016 Nov; 44(11):1044-1058.e5. PubMed ID: 27473563
[TBL] [Abstract][Full Text] [Related]
8. Development of ET, primary myelofibrosis and PV in mice expressing JAK2 V617F.
Shide K; Shimoda HK; Kumano T; Karube K; Kameda T; Takenaka K; Oku S; Abe H; Katayose KS; Kubuki Y; Kusumoto K; Hasuike S; Tahara Y; Nagata K; Matsuda T; Ohshima K; Harada M; Shimoda K
Leukemia; 2008 Jan; 22(1):87-95. PubMed ID: 18033315
[TBL] [Abstract][Full Text] [Related]
9. JAK2 V617F impairs hematopoietic stem cell function in a conditional knock-in mouse model of JAK2 V617F-positive essential thrombocythemia.
Li J; Spensberger D; Ahn JS; Anand S; Beer PA; Ghevaert C; Chen E; Forrai A; Scott LM; Ferreira R; Campbell PJ; Watson SP; Liu P; Erber WN; Huntly BJ; Ottersbach K; Green AR
Blood; 2010 Sep; 116(9):1528-38. PubMed ID: 20489053
[TBL] [Abstract][Full Text] [Related]
10. Current diagnostic criteria for the chronic myeloproliferative disorders (MPD) essential thrombocythemia (ET), polycythemia vera (PV) and chronic idiopathic myelofibrosis (CIMF).
Michiels JJ; Bernema Z; Van Bockstaele D; De Raeve H; Schroyens W
Pathol Biol (Paris); 2007 Mar; 55(2):92-104. PubMed ID: 16919893
[TBL] [Abstract][Full Text] [Related]
11. Megakaryocytic morphology and clinical parameters in essential thrombocythemia, polycythemia vera, and primary myelofibrosis with and without JAK2 V617F.
Vytrva N; Stacher E; Regitnig P; Zinke-Cerwenka W; Hojas S; Hubmann E; Porwit A; Bjorkholm M; Hoefler G; Beham-Schmid C
Arch Pathol Lab Med; 2014 Sep; 138(9):1203-9. PubMed ID: 25171702
[TBL] [Abstract][Full Text] [Related]
12. JAK2-V617F-mutated myeloproliferative neoplasms reveal different allele burden within hematopoietic cell lineages: a microdissection study of bone marrow trephine biopsies.
Kreft A; Kindler T; Springer E; Kirkpatrick CJ
Virchows Arch; 2011 Nov; 459(5):521-7. PubMed ID: 22006129
[TBL] [Abstract][Full Text] [Related]
13. JAK2V617F expression in mice amplifies early hematopoietic cells and gives them a competitive advantage that is hampered by IFNα.
Hasan S; Lacout C; Marty C; Cuingnet M; Solary E; Vainchenker W; Villeval JL
Blood; 2013 Aug; 122(8):1464-77. PubMed ID: 23863895
[TBL] [Abstract][Full Text] [Related]
14. Ratio of mutant JAK2-V617F to wild-type Jak2 determines the MPD phenotypes in transgenic mice.
Tiedt R; Hao-Shen H; Sobas MA; Looser R; Dirnhofer S; Schwaller J; Skoda RC
Blood; 2008 Apr; 111(8):3931-40. PubMed ID: 18160670
[TBL] [Abstract][Full Text] [Related]
15. JAK2-v617F mutation is associated with clinical and laboratory features of myeloproliferative neoplasms.
Duletić AN; Dekanić A; Hadzisejdić I; Kusen I; Matusan-Ilijas K; Grohovac D; Grahovac B; Jonjić N
Coll Antropol; 2012 Sep; 36(3):859-65. PubMed ID: 23213945
[TBL] [Abstract][Full Text] [Related]
16. JAK2 exon 12 mutant mice display isolated erythrocytosis and changes in iron metabolism favoring increased erythropoiesis.
Grisouard J; Li S; Kubovcakova L; Rao TN; Meyer SC; Lundberg P; Hao-Shen H; Romanet V; Murakami M; Radimerski T; Dirnhofer S; Skoda RC
Blood; 2016 Aug; 128(6):839-51. PubMed ID: 27288519
[TBL] [Abstract][Full Text] [Related]
17. A role for reactive oxygen species in JAK2 V617F myeloproliferative neoplasm progression.
Marty C; Lacout C; Droin N; Le Couédic JP; Ribrag V; Solary E; Vainchenker W; Villeval JL; Plo I
Leukemia; 2013 Nov; 27(11):2187-95. PubMed ID: 23558526
[TBL] [Abstract][Full Text] [Related]
18. JAK2 exon 12 mutations in polycythemia vera and idiopathic erythrocytosis.
Scott LM; Tong W; Levine RL; Scott MA; Beer PA; Stratton MR; Futreal PA; Erber WN; McMullin MF; Harrison CN; Warren AJ; Gilliland DG; Lodish HF; Green AR
N Engl J Med; 2007 Feb; 356(5):459-68. PubMed ID: 17267906
[TBL] [Abstract][Full Text] [Related]
19. The JAK2 V617F allele burden in essential thrombocythemia, polycythemia vera and primary myelofibrosis--impact on disease phenotype.
Larsen TS; Pallisgaard N; Møller MB; Hasselbalch HC
Eur J Haematol; 2007 Dec; 79(6):508-15. PubMed ID: 17961178
[TBL] [Abstract][Full Text] [Related]
20. Proteomic study of the impact of the JAK2-V617F mutation on the phenotype of essential thrombocythemia.
Mossuz P; Arlotto M; Hermouet S; Bouamrani A; Lippert E; Girodon F; Dobo I; Vincent P; Cahn JY; Berger F
Exp Hematol; 2008 Dec; 36(12):1642-7. PubMed ID: 18838204
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]